Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Phase 3

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Lebrikizumab

First Posted Date: 2022-05-12

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT05372419

Locations: 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
Wallace Medical Group, Inc., Los Angeles, California, United States
🇺🇸
Clinical Science Institute, Santa Monica, California, United States

and more 32 locations

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Phase 3

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Lebrikizumab

First Posted Date: 2022-05-11

Last Posted Date: 2024-11-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT05369403

Locations: 🇺🇸
Direct Helpers Research Center, Hialeah, Florida, United States
🇺🇸
Skin Care Physicians of Georgia, Macon, Georgia, United States
🇺🇸
Miami Dermatology and Laser Research, Miami, Florida, United States

and more 34 locations

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Phase 3

Completed

Conditions: Diabetes
Type 2 Diabetes

Interventions: Drug: Insulin Efsitora Alfa
Drug: Insulin Degludec

First Posted Date: 2022-05-05

Last Posted Date: 2024-08-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 928

Registration Number: NCT05362058

Locations: 🇺🇸
NorCal Medical Research, Inc, Greenbrae, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸
East Coast Institute for Research, LLC, Jacksonville, Florida, United States

and more 110 locations

A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3556050

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 106

Registration Number: NCT05341102

Locations: 🇺🇸
Medpace Clinical Pharmacology, LLC, Cincinnati, Ohio, United States

A Study of Two Different Formulations of LY3502970 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3502970

First Posted Date: 2022-04-22

Last Posted Date: 2022-09-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT05341089

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Selpercatinib

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT05338476

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT05338515

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2022-04-21

Last Posted Date: 2022-04-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05338489

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Selpercatinib
Drug: Ranitidine
Drug: Omeprazole

First Posted Date: 2022-04-21

Last Posted Date: 2024-10-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT05338502

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3549492
Drug: Placebo
Drug: Atorvastatin
Drug: Midazolam

First Posted Date: 2022-04-14

Last Posted Date: 2024-05-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT05327595

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy